Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an exploratory analysis from the FLAURA2 study, which indicates that baseline levels of plasma EGFR mutation may be prognostic and pr...
Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast cancer, for whom this treatment work...